Holen Sie sich die Stockscreener-App
114.48
0.29%
0.24
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$114.24
Offen:
$114.98
24-Stunden-Volumen:
322.49K
Relative Volume:
0.22
Marktkapitalisierung:
$12.78B
Einnahmen:
$2.90B
Nettoeinkommen (Verlust:
$239.11M
KGV:
54.26
EPS:
2.1097
Netto-Cashflow:
$492.62M
1W Leistung:
+1.80%
1M Leistung:
+2.25%
6M Leistung:
+12.78%
1J Leistung:
+32.52%
1-Tages-Spanne:
$113.73
$115.51
1-Wochen-Bereich:
$107.73
$117.37
52-Wochen-Spanne:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, NTRA, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
114.52 | 12.06B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
587.30 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.78 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
588.64 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
321.32 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
144.78 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
RVTY|Revvity Inc|Price:108.020|Chg%:-2.450 - TradingKey
Revvity Inc. stock underperforms Monday when compared to competitors - MarketWatch
Revvity Inc (RVTY) Cash Flow - TradingKey
Revvity Inc (RVTY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revvity Market Sentiment - Benzinga España
Revvity Inc (RVTY) Income Statement - TradingKey
RVTY|Revvity Inc|Price:111.500|Chg%:+1.030 - TradingKey
Revvity Inc (RVTY) Balance Sheet - TradingKey
Revvity Inc (RVTY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revvity, Inc. (RVTY) Stock Analysis: Potential Upside and Solid Revenue Growth in the Healthcare Sector - DirectorsTalk Interviews
Revvity Inc (RVTY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revvity stock holds firm as diagnostics and life sciences revenue support valuation - Ad-hoc-news.de
PKI5144058 Bond Risk Profile - TradingView
RVTY|Revvity Inc|Price:110.470|Chg%:-2.700 - TradingKey
Revvity, Inc. (RVTY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Revvity, Inc. (RVTY) stock price, news, quote and history - Yahoo Finance Australia
Revvity, Inc. (RVTY) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
PKI5144058 Bond Profile — Key Metrics - TradingView
Revvity, Inc. (RVTY) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Revvity, Inc. (RVTY) Stock Forecasts - Yahoo! Finance Canada
Revvity Inc. stock underperforms Friday when compared to competitors - MarketWatch
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs - Zacks Investment Research
Revvity Inc (RVTY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revvity Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs - Yahoo Finance
Revvity Inc (RVTY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Sell Alert: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
Revvity (NYSE: RVTY) VP Gonzales sells 85 shares under 10b5-1 plan - Stock Titan
How Revvity’s (RVTY) Startup Software Push and ESG Disclosures Reframe Its Competitive Positioning - simplywall.st
Revvity to Launch Signals for Startups for Emerging Biotech Companies - The Globe and Mail
Revvity, Inc. (PKN) Q3 2022 Earnings ReportResults, Call & Slides - TipRanks
Revvity (RVTY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Revvity Inc. Stock Slides 3.4%, Underperforms Peers - webull.com
Revvity stock holds steady as Q1 2026 growth and margin expansion underpin valuation - Ad-hoc-news.de
Precision Trading with Revvity Inc. (RVTY) Risk Zones - Stock Traders Daily
Revvity Inc (RVTY) Stock Down 3.4% -- Now Undervalued? GF Score: 72/100 - GuruFocus
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One - 01net
Revvity (RVTY) Receives a Buy from Leerink Partners - The Globe and Mail
RVTY (RVTY) investor files notice to sell 85 common shares - Stock Titan
Revvity (NYSE: RVTY) removes 1.875% notes due 2026 from NYSE listing - Stock Titan
Revvity launches “Signals for Startups” to give emerging biotechs an enterprise-grade digital edge - Indian Chemical News
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure - Lelezard
Revvity stock trades steadily as recent earnings highlight margin focus - AD HOC NEWS
PKI5144059 Bond Coupon Profile — Rate & Payments - TradingView
PKI5144059 Bond Profile — Key Metrics - TradingView
XS1405780617 Bond Coupon Profile — Rate & Payments - TradingView
XS1405780617 Bond Risk Profile - TradingView
PKI5255604 Bond Risk Profile - TradingView
XS1405780617 Bond Profile — Key Metrics - TradingView
Revvity stock trades steady as genomics and diagnostics revenue underpins valuation - Ad-hoc-news.de
Revvity, Inc. (PKN) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.06%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):